Condition: Alcohol Use Disorder · Sponsor: Indiana University
The investigators assess whether guanfacine extended release (GXR; 3mg/d) compared with placebo (PBO) will attenuate drinking and drinking-related factors in N=200 men and women with Alcohol Use Disorder (AUD) across 12-weeks.
This description comes directly from the study's public registry record.
Helen C Fox, PhD · 2036719643 · helfox@iu.edu
Mitch Smith · 3172785475 · smithmib@iu.edu
Always discuss trial participation with your own doctor first.
| The Stark Neuroscience Building (Goodman Hall) | Indianapolis, Indiana, United States | Recruiting |
| Rutgers School of Health Professionals | Newark, New Jersey, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06629259